Abstract
COVID-19 can trigger a systemic inflammatory response that in some cases leads to severe lung involvement, multisystem dysfunction, and death. Dexamethasone therapy, because of its potent anti-inflammatory effects, has been proposed for the management of hospitalized patients with severe COVID-19. The subject of this article is to discuss potential strategies to tackle Strongyloides hyperinfection in hospitalized patients with COVID-19 receiving dexamethasone therapy in low- and middle-income countries. In this context, dexamethasone treatment has been found to be generally safe. However, its use in people coinfected with undetected Strongyloides stercoralis increases the risk for Strongyloides hyperinfection/dissemination a potentially fatal complication. Infection caused by S. stercoralis may remain asymptomatic or with mild symptoms in humans for several years. Early detection and specific treatment prevent a fatal evolution of this complication, but the challenge is to screen before corticosteroid therapy. In some cases, presumptive treatment may be justified. Ivermectin is the gold standard for treatment.
【초록키워드】 Corticosteroid, COVID-19, Dexamethasone, Ivermectin, Treatment, Evolution, Anti-inflammatory effects, therapy, severe COVID-19, lung involvement, Human, risk, hospitalized patients, Asymptomatic, management, Early detection, death, gold, mild symptoms, Safe, in some, dysfunction, Mild symptom, subject, gold standard, systemic inflammatory response, fatal complication, specific treatment, corticosteroid therapy, Prevent, Strongyloides stercoralis, caused, receiving, increase, hospitalized patient, with COVID-19, 【제목키워드】 Strategy, Hyperinfection,